Patent application number | Description | Published |
20080208317 | Anchoring Device for Stent - Disclosed is a stent supporting device. The support device anchors a stent in a manner such that an anchoring stent is inserted into a branch blood vessel adjacent to an artery in which the stent is disposed, and the anchoring stent is connected to the stent. Accordingly, the support device is safe because it does not use subsidiary members such as screws, which can injure a blood vessel. Further, since the support device allows the stent to have a length corresponding to the size of a treatment site, that is, the stent does not need to be longer than the size of the treatment site, it is easy to install the stent. | 08-28-2008 |
20090087422 | Pharmaceutical composition for alleviation and treatment of ischemic conditions and method for delivering the same - The present invention relates to pharmaceutical compositions for treating diseases and conditions caused by ischemia. The pharmaceutical compositions contain a conjugate of a phospholipase (PL) polypeptide and a protein transduction domain (PTD). PLC-δ plays a major role in the regulation of cytosolic calcium levels. During myocardial ischemia, cytosolic calcium accumulation mediates pathogenic changes. According to the present invention, ischemic diseases or conditions leading to hypoxia in tissues, such as the heart and the brain, can be prevented or alleviated by administration of a PTD-PL conjugate. | 04-02-2009 |
20090269842 | TRANSMEMBRANE DELIVERY PEPTIDE AND BIO-MATERIAL COMPRISING THE SAME - The present invention relates to a transmembrane delivery peptide derived from human in which a target protein may be easily delivered into cells, and a recombinant vector comprising a nucleic acid coding the peptide. More specifically, the present invention relates to the transmembrane delivery peptide having an amino acid sequence described in SEQ ID No. 1 including 11 amino acids of specific sites in amino acid sequences of human G protein alpha 12, and a recombinant vector comprising a nucleic acid coding the same, a transformant prepared by introducing said recombinant vector, and the like. Since transmembrane delivery peptides of the present invention can be efficiently delivered into cells, they may be usefully used for the purposes of delivering various target materials, including proteins, nucleic acid, drugs and the like. | 10-29-2009 |
20100112562 | Mutation Implicated in Abnormality of Cardiac Sodium Channel Function - A novel mutation in the SCN5A gene is associated with loss of cardiac sodium channel function. Analysis of the novel mutation provides an early diagnosis of subjects with cardiac diseases or disorders caused by loss of cardiac sodium channel function, particularly Brugada syndrome. Diagnostic methods include analyzing the sequences of the SCN5A gene or protein of an individual to be tested and comparing them with the sequences of the native, nonvariant SCN5A gene or protein. Pre-symptomatic diagnosis of these syndromes will enable practitioners to treat these disorders using existing medical therapy, e.g., using sodium channel blockers or through electrical stimulation. | 05-06-2010 |
20110159479 | GENETIC POLYMORPHISMS IN THE CYTOCHROME P450 GENE WITH CLOPIDOGREL RESISTANCE - The present invention relates to a method for predicting the resistance of a human subject to clopidogrel, which comprises detecting the presence or absence of a A allele at position 636 of exon 4 in the CYP2C19 gene, wherein the presence of the A allele is indicative of a clopidogrel resistance. The present method may be very useful in predicting the resistance of a human subject to clopidogrel and contribute to more effective chemotherapy for patients having coronary artery disease and drug-eluting stent. | 06-30-2011 |
20120116500 | H-Side Branch Stent - Provided is an H-side branch stent including a first stent having a plurality of cells and a hollow cylindrical shape, at least one bridge having one end connected to a distal end of the first stent, and a second stent having a front end connected to the other end of the bridge, and having a plurality of cells and a hollow cylindrical shape. Accordingly, the H-side branch stent can prevent re-stenosis of the opening of the branch blood vessel since the stent can completely support an inner circumference of an opening of a branch blood vessel in a circumferential direction, and prevent blood flow disturbance because stents are not densely concentrated to a boundary between a main blood vessel and the branch blood vessel and some regions of the stent do not project into the main blood vessel. | 05-10-2012 |
20130109015 | Single Nucleotide Polymorphisms Associated with Left Ventricular Hypertrophy and Use Thereof | 05-02-2013 |
20130164847 | USE OF A PROTEIN TYROSINE KINASE INHIBITOR FOR INDUCING THE DIFFERENTIATION OF MESENCHYMAL STEM CELLS INTO CARDIOGENIC CELLS - The present invention pertains to methods of using protein tyrosine kinase (PTK) inhibitors for inducing cell differentiation of mesenchymal stem cells into cardiac cells, and a pharmaceutical composition comprising the differentiated cardiac cells thereof to treat heart diseases. The transplantation of mesenchymal stem cells to the heart provides immunological and functional improvements, but does not provide electrical stability. However, the mesenchymal stem cells treated with PTK inhibitors are induced to be differentiated into cardiogenic cells to provide electrical stability as the electromechanical integration with host heart tissue is improved, and it is thus possible to effectively treat cardiac diseases such as cardiac infarction, cardiac insufficiency, arrhythmia and the like. | 06-27-2013 |
20130236969 | Use of Compounds for Inducing Differentiation of Mesenchymal Stem Cells to Chondrocytes - Use of a compound of Formula 1 for inducing differentiation of mesenchymal stem cells to chondrocytes, and a pharmaceutical composition for treating a cartilage disease, which includes chondrocytes in which differentiation from mesenchymal stem cells is induced by the compound of Formula 1, are provided. Differentiation of the mesenchymal stem cells treated with the compound of Formula 1 to chondrocytes is specifically induced, and thus the compound can be used to effectively treat a cartilage disease such as arthritis, cartilage damage, and a cartilage defect. | 09-12-2013 |
20140256034 | BIO-PIN - A bio-pin is provided. The bio-pin can be used for cell transfer and treatment, cell tracing, and targeting of specific tissues and cells using a peptide-based complex in which a cell-penetrating peptide or a cell-adhesive peptide is bound to one or both ends of a cell membrane protein, and used in a molecular imaging system, a medical appliance, and the like. | 09-11-2014 |